Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
QUINASPEN SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): QUINASPEN QUINASPEN 5 mg TABLET QUINASPEN 10 mg TABLET QUINASPEN 20 mg TABLET QUINASPEN 40 mg TABLET COMPOSITION Each tablet contains: QUINASPEN 5 mg TABLET: Quinapril hydrochloride equivalent to 5 mg quinapril . QUINASPEN 10 mg TABLET Quinapril hydrochloride equivalent to 10 mg quinapril. QUINASPEN 20 mg TABLET: Quinapril hydrochloride equivalent to 20 mg quinapril. QUINASPEN 40 mg TABLET: Quinapril hydrochloride equivalent to 40 mg quinapril. PHARMACOLOGICAL CLASSIFICATION A 7.1.3 Other hypotensives. PHARMACOLOGICAL ACTION Quinapril inhibits angiotensin I-converting enzyme (ACE) activity. It inhibits the conversion of the relatively inactive angiotensin I to the active angiotensin II. Angiotensin II is a potent vasocontrictor and stimulates the release of aldosterone. Decreased angiotensin II levels result in a decrease in vasopressor activity and reduction in aldosterone secretion, which may result in small increases in serum potassium. It is also thought that ACE inhibition may inhibit degradation of bradykinin, leading to increased bradykinin levels. Pharmacokinetics: The extent of absorption after oral administration is approximately 60%, with wide variability between patients. The plasma half-life is approximately one hour, which is increased in renal impairment. The time to achieve peak serum concentration is within one hour. Quinapril is renally eliminated and excreted 100% unchanged in the urine. INDICATIONS QUINASPEN tablets are indicated for the following: • Hypertension: QUINASPEN is indicated for the treatment of mild to moderate hypertension. QUINASPEN is effective as monotherapy or concomitantly with diuretics in patients wit Read the complete document